 |
        |
Klaus Breiner, Ph.D.Board Member Dr. Breiner joined the ORTHOCON® Board of Directors in 2006 and represents BB BIOTECH VENTURES’ investment in the company. He currently is an investment advisor for BB BIOTECH VENTURES. He has invested in a broad range of life science companies. Before becoming a venture capitalist, he was a business consultant with Booz Allen & Hamilton in Zurich and a researcher at the Swiss Federal Institute of Technology (ETH) in Zurich and at the Center for Molecular Biology in Heidelberg (ZMBH). Dr. Breiner holds an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in Molecular Biology from the University of Heidelberg. He has authored several scientific publications and has received prestigious academic awards and fellowships. Return to Leadership |
 |
||||||
 |
 |
ORTHOCON® estimates that over 3.5 million patients undergoing surgeries in the United States and Europe each year could benefit from the intraoperative use of HEMASORB.
 |
|
ORTHOCON® Names David J. Hart Vice President of Business Operations
March 15, 2012 - Click to Download Canaan Partners Closes $600 Million Fund, Canaan IX January 9, 2012 - Click to Read More |
||
|
||||||
